Martin W - Search Results

1

Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island.

Koita OA, Dabitao D, Mahamadou I, Tall M, Dao S, Tounkara A, Guiteye H, Noumsi C, Thiero O, Kone M, Rivera D, McMurry JA, Martin W, De Groot AS. Koita OA, et al. Among authors: martin w. Hum Vaccin. 2006 May-Jun;2(3):119-28. doi: 10.4161/hv.2869. Epub 2006 May 25. Hum Vaccin. 2006. PMID: 17012903

2

Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes.

McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. McMurry J, et al. Among authors: martin w. Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):95-105. doi: 10.1016/j.tube.2004.09.005. Epub 2004 Dec 25. Tuberculosis (Edinb). 2005. PMID: 15687033

3

Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping.

De Groot AS, Rayner J, Martin W. De Groot AS, et al. Among authors: martin w. Dev Biol (Basel). 2003;112:71-80. Dev Biol (Basel). 2003. PMID: 12762506

4

De-immunization of therapeutic proteins by T-cell epitope modification.

De Groot AS, Knopp PM, Martin W. De Groot AS, et al. Among authors: martin w. Dev Biol (Basel). 2005;122:171-94. Dev Biol (Basel). 2005. PMID: 16375261 Review.

5

HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).

De Groot AS, Kazi ZB, Martin RF, Terry FE, Desai AK, Martin WD, Kishnani PS. De Groot AS, et al. Among authors: martin wd, martin rf. Clin Immunol. 2019 Mar;200:66-70. doi: 10.1016/j.clim.2019.01.009. Epub 2019 Jan 31. Clin Immunol. 2019. PMID: 30711607 Free PMC article.

6

Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome.

De Groot AS, Saint-Aubin C, Bosma A, Sbai H, Rayner J, Martin W. De Groot AS, et al. Among authors: martin w. Emerg Infect Dis. 2001 Jul-Aug;7(4):706-13. doi: 10.3201/eid0704.010419. Emerg Infect Dis. 2001. PMID: 11585536 Free PMC article.

7

Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation.

Meyers LM, Gutiérrez AH, Boyle CM, Terry F, McGonnigal BG, Salazar A, Princiotta MF, Martin WD, De Groot AS, Moise L. Meyers LM, et al. NPJ Vaccines. 2021 May 13;6(1):71. doi: 10.1038/s41541-021-00331-6. NPJ Vaccines. 2021. PMID: 33986292 Free PMC article.

8

From genome to vaccine: in silico predictions, ex vivo verification.

De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, Martin W, Saint-Aubin C. De Groot AS, et al. Among authors: martin w. Vaccine. 2001 Aug 14;19(31):4385-95. doi: 10.1016/s0264-410x(01)00145-1. Vaccine. 2001. PMID: 11483263 Review.

9

Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.

Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. Koren E, et al. Among authors: martin w. Clin Immunol. 2007 Jul;124(1):26-32. doi: 10.1016/j.clim.2007.03.544. Epub 2007 May 9. Clin Immunol. 2007. PMID: 17490912

10

Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules.

Liso A, Colau D, Benmaamar R, De Groot A, Martin W, Benedetti R, Specchia G, Martelli MP, Coulie P, Falini B. Liso A, et al. Among authors: martin w. Leukemia. 2008 Feb;22(2):424-6. doi: 10.1038/sj.leu.2404887. Epub 2007 Aug 9. Leukemia. 2008. PMID: 17690700 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,317 results

Search Page

Filters